Degenerative Disc Disease Pipeline Landscape Analysis of 30+ Companies by DelveInsight

0

DelveInsight’s report, “Degenerative Disc Disease Pipeline Insight, 2022,” provides comprehensive insights on 30+ companies and 30+ drugs in development in the degenerative disc disease pipeline landscape. It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

In the Degenerative Disc Disease Pipeline report, a detailed description of the drug is given including the drug’s mechanism of action, clinical studies, NDA approvals (if any) and product development activities including the technology, degenerative disc disease collaborations, licensing, mergers and acquisition, financing, designations, and other product-related details.

Key Takeaways from Degenerative Disc Disease Pipeline Analysis Report

  • DelveInsight’s Degenerative Disc Disease Pipeline Analysis depicts a robust space with over 30 active players working to develop over 38 pipeline therapies for the treatment of Degenerative Disc Disease.
  • Major degenerative disc disease companies are working such as Affibody, Celgene Corporation, UCB, Vivex Biomedical, Inc., Lynk Pharmaceuticals, Huabo Biopharm, Amgen, Izana Bioscience, Takeda, Merck Serono, MoonLake Immunotherapeutics and others.
  • Promising therapies for degenerative disc disease such as Izokibep, CC 99677, Bimekizumab and others
  • Companies and academics are working to assess challenges and seek out opportunities that can influence degenerative disc disease R&D. The therapies under development are focused on new approaches to treat/improve degenerative disc disease.

Request a sample and learn about recent breakthroughs happening in the Degenerative Disc Disease Pipeline landscape @ Degenerative Disc Disease Pipeline Insights

Overview of Degenerative Disc Disease

Degenerative disc disease (spondylosis) is used to describe the regular changes that occur in human intervertebral discs as they age. Discs generally act as shock absorbers for the human spine, allowing the body to flex, bend and twist. With aging, there are several other factors, such as drying up of the disc, tearing of the outer core of the disc during daily activities, as well as sports and injuries causing swelling, pain and instability, contributing to the development of a degenerative disc. sickness. This disease often leads to several types of disorders, such as lumbar spinal stenosis, spondylolisthesis and retrospondylolisthesis. About 90% of people experience an episode of debilitating back pain sometime later in life. The majority of cases encountered are asymptomatic. Vertebral discs consist of a soft inner core and a hard outer wall.

Recent Development Activities in the Degenerative Disc Disease Pipeline

  • Celgene Corporation, is developing drug CC 99677, as a treatment for ankylosing spondylitis (AS). Inhibition of MK2 by CC-99677 is a promising approach for the treatment of inflammatory diseases. Currently, the phase II study of CC-99677 in patients with ankylosing spondylitis (AS) is ongoing.
  • Bimekizumab is a humanized monoclonal IgG1 antibody designed to selectively and directly inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes. Currently, the drug is in phase III clinical trial evaluation for the treatment of ankylosing spondylitis.
  • Inmagene’s investigational candidate, Izokibep (IMG-020), is a novel bispecific fusion protein, potently targeting both IL-17A subunits as well as albumin. Izokibep was specifically designed to leverage the strengths of Affibody’s technology platform to create a very small protein drug (18 kDa, approximately one-eighth the size of an antibody) with a very high apparent affinity for IL-17A (KD ~300fM, approximately 1000X of a typical IL-17 antibody) and antibody-like half-life due to high binding affinity (KD ~50 pM) to serum albumin. These characteristics lead to the potential for optimal efficacy in convenient, less frequent, at-home subcutaneous administration. Izokibep is manufactured in an inexpensive E. coli system, which allows for a significantly lower manufacturing cost/dose than a typical antibody. Affibody is developing IMG-020 (izokibep) in a global Phase II clinical trial in the United States, China and South Korea for the treatment of ankylosing spondylitis, with a focus on patients difficult to treat by increasing dose and exposure.

Emerging drugs for degenerative disc disease

  • Izokibep: Afficorps
  • CC 99677: Celgene Corporation
  • Bimekizumab: UCB

Learn about new and emerging therapies in the Degenerative Disc Disease pipeline in Degenerative Disc Disease Clinical Trials

Therapeutic Analysis of the Degenerative Disc Diseases Pipeline

Approx. Over 30 key companies developing therapies for degenerative disc disease. Among the companies whose drug candidates for degenerative disc disease are at the most advanced stage, ie in phase III, is UCB.

Scope of the Degenerative Disc Disease Pipeline Report

  • Coverage – Global
  • Degenerative disc disease Rating by product type
  • Assessment of Degenerative Disc Disease by Stage and Product Type
  • Degenerative disc disease Assessment by route of administration
  • Degenerative disc disease Assessment by stage and route of administration
  • Degenerative disc disease Evaluation by type of molecule
  • Evaluation of degenerative disc disease by stage and type of molecule
  • Degenerative Disc Disease Companies – Affibody, Celgene Corporation, UCB, Vivex Biomedical, Inc., Lynk Pharmaceuticals, Huabo Biopharm, Amgen, Izana Bioscience, Takeda, Merck Serono, MoonLake Immunotherapeutics and others.
  • Degenerative disc disease Pipeline treatments such as Izokibep, CC 99677, Bimekizumab and others

Contents

  1. Introduction
  2. Summary
  3. Degenerative disc disease: overview
  4. Pipeline therapeutics
  5. Therapeutic assessment
  6. Degenerative Disc Disease – Analytical Perspective from DelveInsight
  7. Late-stage products (Phase III)
  8. Bimekizumab: UCB
  9. Medication profiles in the detailed report…..
  10. Mid-term products (Phase II)
  11. CC 99677: Celgene Corporation
  12. Medication profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company name
  15. Medication profiles in the detailed report…..
  16. Products in the preclinical and discovery phase
  17. Drug name: Company name
  18. Medication profiles in the detailed report…..
  19. Inactive products
  20. Degenerative Disc Disease Key Companies
  21. Degenerative Disc Disease Key Products
  22. Degenerative Disc Disease – Unmet Needs
  23. Degenerative Disc Disease – Market Drivers and Barriers
  24. Degenerative Disc Disease – Future Perspectives and Conclusion
  25. Degenerative Disc Disease Analyst Opinions
  26. Degenerative Disc Disease Key Companies
  27. Annex

Key issues

Current treatment scenario and emerging therapies:

  • How many companies are developing drugs for degenerative disc disease?
  • How many degenerative disc disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage and late-stage development for the treatment of degenerative disc disease?
  • What are the key collaborations (industry-industry, industry-academia), mergers and acquisitions, licensing activities related to degenerative disc disease therapy?
  • What are the recent trends, types of drugs and new technologies developed to overcome the limitations of existing therapies?
  • What are the current clinical studies for degenerative disc disease and their status?
  • What are the key designations that have been granted to pipeline drugs?

For more information about the therapeutics in the Degenerative Disc Disease pipeline, contact Degenerative Disc Disease Companies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Yash Bhardwaj
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Share.

Comments are closed.